

# GLOBAL IBS-C DRUG MARKET FORECAST 2017-2025

<https://marketpublishers.com/r/GE002F90959EN.html>

Date: July 2017

Pages: 112

Price: US\$ 2,500.00 (Single User License)

ID: GE002F90959EN

## Abstracts

### KEY FINDINGS

The global IBS-C drug market is expected to grow at a CAGR of 6.30% during the forecast period of 2017 – 2025. The major factors driving this market are:

Modern dietary habits taking a toll on the health

Psychological factors affecting irritable bowel syndrome

Improved and efficient drugs in pipeline with several first-in-class molecules

Availability of effective drugs in the market

### MARKET INSIGHTS

The global IBS-C drug market is segmented on the type of drug and prescription.

Drugs type are further segmented into:

Lubiprostone

Linaclotide

Stimulant Laxatives

Osmotic Laxatives

## Others

Of these, lubiprostone is a highly popular drug in the market.

Prescription type is further segmented into:

Prescribed

Over the Counter

Over the counter drugs are leading this segment since no prescription from a doctor is required.

## REGIONAL INSIGHTS

The global IBS-C drug market is geographically divided into the following regions:

North America - U.S. & Canada

Asia Pacific – China, Japan, and RoAPAC

Europe – UK, Germany, and RoE

Rest of World – MENA, and Latin America

Of these, the North America region is anticipated to dominate the global IBS-C drug market over the forecast period on account of its highly developed healthcare systems and advanced medical devices industry.

## COMPETITIVE INSIGHTS

Some of the major players in the global IBS-C drug market are:

Nestle

Catalent Pharma Solutions

Abbot Laboratories

Sucampo Pharmaceuticals

Synergy Pharmaceuticals

Novartis

## Contents

### **1. RESEARCH SCOPE**

- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS

### **2. RESEARCH METHODOLOGY**

- 2.1. SOURCES OF DATA
  - 2.1.1. SECONDARY DATA
  - 2.1.2. PRIMARY DATA
- 2.2. TOP DOWN APPROACH
- 2.3. BOTTOM UP APPROACH
- 2.4. DATA TRIANGULATION
- 2.5. ESTIMATION METHODOLOGY

### **3. EXECUTIVE SUMMARY**

- 3.1. MARKET SUMMARY

### **4. MARKET OVERVIEW**

- 4.1. MARKET DEFINITION
- 4.2. KEY MARKET INSIGHTS
- 4.3. ATTRACTIVE INVESTMENT SCENARIO
- 4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
- 4.5. DRIVERS
  - 4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
  - 4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
  - 4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
  - 4.5.4. IBS CAN BE A HERITABILITY ISSUE
  - 4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
- 4.6. RESTRAINTS
  - 4.6.1. STRICT FDA REGULATIONS
  - 4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE

#### 4.7. OPPORTUNITIES

4.7.1. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET

4.7.2. HIGH UNMET NEEDS

#### 4.8. CHALLENGES

4.8.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS

### **5. GLOBAL IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 (\$ MILLION)**

#### 5.1. OVERVIEW

5.1.1. LUBIPROSTONE

5.1.2. LINACLOTIDE

5.1.3. STIMULANT LAXATIVES

5.1.4. OSMOTIC LAXATIVES

5.1.5. OTHERS (PSYLLIUM) – QUALITATIVE INFORMATION

5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, \$ MILLION)

### **6. GLOBAL IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 (\$ MILLION)**

#### 6.1. PRESCRIBED DRUGS

6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 (\$ MILLION)

6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 (\$ MILLION)

#### 6.2. OVER THE COUNTER DRUGS

### **7. KEY ANALYTICS**

#### 7.1. PORTERS FIVE FORCE ANALYSIS

7.1.1. INTENSITY OF COMPETITIVE RIVALRY/COMPETITION AMONG THE

7.1.2. BARGAINING POWER OF SUPPLIERS

7.1.3. BARGAINING POWER OF BUYERS

7.1.4. THREAT OF SUBSTITUTE PRODUCTS

7.1.5. THREAT OF NEW ENTRANTS

#### 7.2. VENDOR LANDSCAPE

#### 7.3. OPPORTUNITY MATRIX

### **8. GLOBAL IBS-C DRUG MARKET BY GEOGRAPHY 2017-2025 (\$ MILLION)**

#### 8.1. NORTH AMERICA

- 8.1.1. US
- 8.1.2. CANADA
- 8.2. EUROPE
  - 8.2.1. UK
  - 8.2.2. GERMANY
  - 8.2.3. REST OF THE EUROPE
- 8.3. ASIA PACIFIC
  - 8.3.1. CHINA
  - 8.3.2. JAPAN
  - 8.3.3. REST OF ASIA PACIFIC
- 8.4. REST OF THE WORLD
  - 8.4.1. MIDDLE EAST AND AFRICA
  - 8.4.2. LATIN AMERICA
  - 8.4.3. REST OF THE ROW

## **9. COMPANY PROFILES**

- 9.1. CATALENT PHARMACEUTICALS SOLUTIONS
  - 9.1.1. OVERVIEW
  - 9.1.2. PRODUCT PORTFOLIO
  - 9.1.3. SCOT ANALYSIS
  - 9.1.4. STRATEGIC MOVES
- 9.2. NESTLE
  - 9.2.1. OVERVIEW
  - 9.2.2. PRODUCTS PORTFOLIO
  - 9.2.3. SCOT ANALYSIS
  - 9.2.4. STRATEGIC MOVES
- 9.3. ABBOTT LABORATORIES
  - 9.3.1. OVERVIEW
  - 9.3.2. PRODUCT PORTFOLIO
  - 9.3.3. SCOT ANALYSIS
  - 9.3.4. STRATEGIC MOVES
- 9.4. SYNERGY PHARMACEUTICALS
  - 9.4.1. OVERVIEW
  - 9.4.2. PRODUCTS PORTFOLIO
  - 9.4.3. SCOT ANALYSIS
  - 9.4.4. STRATEGIC MOVES
- 9.5. SUCAMPO PHARMACEUTICALS
  - 9.5.1. OVERVIEW

- 9.5.2. PRODUCT PORTFOLIO
- 9.5.3. SCOT ANALYSIS
- 9.5.4. STRATEGIC MOVES
- 9.6. NOVARTIS PHARMA AG
  - 9.6.1. OVERVIEW
  - 9.6.2. PRODUCTS PORTFOLIO
  - 9.6.3. SCOT ANALYSIS
  - 9.6.4. STRATEGIC MOVES
- 9.7. ASTELLAS PHARMACEUTICALS
  - 9.7.1. OVERVIEW
  - 9.7.2. PRODUCT PORTFOLIO
  - 9.7.3. SCOT ANALYSIS
  - 9.7.4. STRATEGIC MOVES
- 9.8. ARDELYX, INC.
  - 9.8.1. OVERVIEW
  - 9.8.2. PRODUCT PORTFOLIO
  - 9.8.3. SCOT ANALYSIS
  - 9.8.4. STRATEGIC MOVES
- 9.9. SYNTHETIC BIOLOGICS, INC.
  - 9.9.1. OVERVIEW
  - 9.9.2. PRODUCT PORTFOLIO
  - 9.9.3. SCOT ANALYSIS
  - 9.9.4. STRATEGIC MOVES
- 9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  - 9.10.1. OVERVIEW
  - 9.10.2. PRODUCT PORTFOLIO
  - 9.10.3. SCOT ANALYSIS
  - 9.10.4. STRATEGIC MOVES
- 9.11. BAMA-GEVE, SLU
  - 9.11.1. OVERVIEW
  - 9.11.2. PRODUCT PORTFOLIO
  - 9.11.3. SCOT ANALYSIS
- 9.12. FERRING BV
  - 9.12.1. OVERVIEW
  - 9.12.2. PRODUCT PORTFOLIO
  - 9.12.3. SCOT ANALYSIS
  - 9.12.4. STRATEGIC MOVES
- 9.13. IRONWOOD PHARMACEUTICALS, INC.
  - 9.13.1. OVERVIEW

- 9.13.2. PRODUCT PORTFOLIO
- 9.13.3. SCOT ANALYSIS
- 9.13.4. STRATEGIC MOVES
- 9.14. SALIX PHARMACEUTICALS LTD
  - 9.14.1. OVERVIEW
  - 9.14.2. PRODUCT PORTFOLIO
  - 9.14.3. SCOT ANALYSIS
  - 9.14.4. STRATEGIC MOVES
- 9.15. NORGINE B.V.
  - 9.15.1. OVERVIEW
  - 9.15.2. PRODUCT PORTFOLIO
  - 9.15.3. SCOT ANALYSIS
  - 9.15.4. STRATEGIC MOVES
- 9.16. PROMETHEUS LABORATORIES INC.
  - 9.16.1. OVERVIEW
  - 9.16.2. PRODUCT PORTFOLIO
  - 9.16.3. SCOT ANALYSIS
  - 9.16.4. STRATEGIC MOVES
- 9.17. ACTAVIS NORDIC A/S
  - 9.17.1. OVERVIEW
  - 9.17.2. PRODUCT PORTFOLIO
  - 9.17.3. SCOT ANALYSIS
  - 9.17.4. STRATEGIC MOVES
- 9.18. ALBIREO PHARMA INC
  - 9.18.1. OVERVIEW
  - 9.18.2. PRODUCT PORTFOLIO
  - 9.18.3. SCOT ANALYSIS
  - 9.18.4. STRATEGIC MOVES
- 9.19. YUHAN CORP
  - 9.19.1. OVERVIEW
  - 9.19.2. PRODUCT PORTFOLIO
  - 9.19.3. SCOT ANALYSIS
  - 9.19.4. STRATEGIC MOVES
- 9.20. ASTRAZENECA PLC
  - 9.20.1. OVERVIEW
  - 9.20.2. PRODUCT PORTFOLIO
  - 9.20.3. SCOT ANALYSIS
  - 9.20.4. STRATEGIC MOVES
- 9.21. THE MENARINI GROUP



9.21.1. OVERVIEW

9.21.2. PRODUCT PORTFOLIO

9.21.3. SCOT ANALYSIS

9.21.4. STRATEGIC MOVES

9.22. ONO PHARMACEUTICAL CO., LTD.

9.22.1. OVERVIEW

9.22.2. PRODUCT PORTFOLIO

9.22.3. SCOT ANALYSIS

9.22.4. STRATEGIC MOVES

## List Of Tables

### LIST OF TABLES

TABLE 1 GLOBAL IBS-C MARKET BY GEOGRAPHY 2017-2025 (\$ MILLION)

TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT  
DRUG MARKET ARE

TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS

TABLE 4 POPULATION OF ASIA BY AGE GROUP IN VARIOUS SUB REGION, JULY  
2013

TABLE 5 GLOBAL IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 (\$ MILLION)

TABLE 6 GLOBAL LUBIPROSTONE MARKET BY REGION, 2017-2025 (\$ MILLION)

TABLE 7 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 8 GLOBAL LINACLOTIDE MARKET BY REGION, 2017-2025 (\$ MILLION)

TABLE 9 PRODUCT PROFILE (LINACLOTIDE)

TABLE 10 GLOBAL STIMULANT LAXATIVES MARKET BY REGION, 2017-2025 (\$  
MILLION)

TABLE 11 GLOBAL BISACODYL MARKET BY REGION, 2017-2025 (\$ MILLION)

TABLE 12 PRODUCT PROFILE (BISACODYL)

TABLE 13 GLOBAL SENNA MARKET BY REGION, 2017-2025 (\$ MILLION)

TABLE 14 PRODUCT PROFILE (SENNA)

TABLE 15 GLOBAL LACTULOSE MARKET BY REGION, 2017-2025 (\$ MILLION)

TABLE 16 PRODUCT PROFILE (LACTULOSE)

TABLE 17 GLOBAL POLYETHYLENE GLYCOL MARKET BY REGION, 2017-2025 (\$  
MILLION)

TABLE 18 PRODUCT PROFILE (POLYETHYLENE GLYCOL)

TABLE 19 PRODUCT PROFILE (PSYLLIUM)

TABLE 20 PIPELINE PRODUCT PROFILE (PLECANATIDE)

TABLE 21 GLOBAL IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 (\$  
MILLION)

TABLE 22 GLOBAL PRESCRIBED DRUG MARKET BY REGION 2017-2025 (\$  
MILLION)

TABLE 23 PRODUCT PROFILE (LUBIPROSTONE)

TABLE 24 BRANDED IBS-C DRUGS MARKET BY REGION, 2017-2025 (\$ MILLION)

TABLE 25 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)

TABLE 26 GENERIC IBS-C DRUG MARKET BY REGION, 2017-2025 (\$ MILLION)

TABLE 27 PRODUCT PROFILE (METAMUCIL)

TABLE 28 GLOBAL OVER THE COUNTER, IBS-C DRUGS MARKET 2017-2025 (\$  
MILLION)

TABLE 29 GLOBAL IBS-C DRUG MARKET BY GEOGRAPHY 2017-2025 (\$ MILLION)

TABLE 30 NORTH AMERICA IBS-C DRUG MARKET 2017-2025 (\$ MILLION)

TABLE 31 EUROPE IBS-C DRUG MARKET 2017-2025 (\$ MILLION)

TABLE 32 APAC IBS-C DRUGS MARKET, 2017-2025, (\$ MILLION)

TABLE 33 ROW IBS-C DRUGS MARKET 2017-2025 (\$ MILLION)

## List Of Figures

### LIST OF FIGURES

FIGURE 1 GLOBAL IBS-C DRUGS MARKET 2017-2025 (\$ MILLION)

FIGURE 2 GLOBAL IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)

FIGURE 3 GLOBAL IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)

FIGURE 4 PREVALENCE OF IBS-C IN THE GLOBAL MARKET

FIGURE 5 DIETS RESPONSIBLE FOR IBS

FIGURE 6 PERCENTAGE OF PERSONS AGED 12 AND OVER WITH DEPRESSION  
BY AGE AND SEX US, 2009-2012

FIGURE 7 DRUGS PULLED OFF FROM THE MARKET

FIGURE 8 LIFESTYLE AND HOME REMEDIES FOR IBS

FIGURE 9 US IBS-C DRUG MARKET 2017-2025 (\$ MILLION)

FIGURE 10 CANADA IBS-C DRUG MARKET 2017-2025 (\$ MILLION)

FIGURE 11 UK IBS-C DRUG MARKET, 2017-2025 (\$ MILLION)

FIGURE 12 GERMANY IBS-C DRUGS MARKET, 2017-2025, (\$ MILLION)

FIGURE 13 REST OF EUROPE IBS-C DRUGS MARKET, 2017-2025, (\$ MILLION)

FIGURE 14 CHINA IBS-C DRUGS MARKET, 2017-2025, (\$ MILLION)

FIGURE 15 CHINESE MEDICINE TCM TREATMENT FOR IBS

FIGURE 16 JAPAN IBS-C DRUGS MARKET 2017-2025, (\$ MILLION)

FIGURE 17 PHARMACEUTICAL MARKET SALES

FIGURE 18 REST OF APAC IBS-C DRUGS MARKET 2017-2025 (\$ MILLION)

FIGURE 19 MENA IBS-C DRUGS MARKET 2017-2025, (\$ MILLION)

FIGURE 20 LATIN AMERICA IBS-C DRUGS MARKET 2017-2025, (\$ MILLION)

FIGURE 21 ROW IBS-C DRUGS MARKET 2017-2025 (\$ MILLION)

## I would like to order

Product name: GLOBAL IBS-C DRUG MARKET FORECAST 2017-2025

Product link: <https://marketpublishers.com/r/GE002F90959EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE002F90959EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970